生物疗法治疗重度哮喘的临床缓解：定义问题。
Clinical remission with biologic therapies in severe asthma: a matter of definition.
机构信息
Wellcome Wolfson Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, UK.
Belfast Health and Social Care NHS Trust, Belfast, UK.
出版信息
Eur Respir J. 2024 Jun 20;63(6). doi: 10.1183/13993003.00160-2024. Print 2024 Jun.
Abstract
摘要
相似文献
1
Clinical remission with biologic therapies in severe asthma: a matter of definition.生物疗法治疗重度哮喘的临床缓解：定义问题。
Eur Respir J. 2024 Jun 20;63(6). doi: 10.1183/13993003.00160-2024. Print 2024 Jun.
2
How Much Do We Know About Clinical Response and Remission to Add-On Biologics in Severe Asthma in a Real-World Setting.在真实世界中，我们对重度哮喘患者加用生物制剂后的临床反应和缓解情况了解多少？
Chest. 2024 May;165(5):e157-e158. doi: 10.1016/j.chest.2023.12.034.
3
Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults.探索成人接受生物治疗后重度哮喘临床缓解的定义和预测因素。
Am J Respir Crit Care Med. 2024 Oct 1;210(7):869-880. doi: 10.1164/rccm.202311-2192OC.
4
Clinical remission after biologic therapy discontinuation in pediatric patients with severe asthma: a case series from a tertiary center.重度哮喘儿科患者停用生物制剂治疗后的临床缓解：来自三级中心的病例系列
J Bras Pneumol. 2024 May 27;50(2):e20230405. doi: 10.36416/1806-3756/e20230405.
5
Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.生物疗法治疗重症哮喘的临床缓解：来自英国重症哮喘注册研究的分析。
Eur Respir J. 2023 Dec 14;62(6). doi: 10.1183/13993003.00819-2023. Print 2023 Dec.
6
Biologics in Asthma: Potential to Achieve Clinical Remission.哮喘中的生物制剂：实现临床缓解的潜力。
Immunol Allergy Clin North Am. 2024 Nov;44(4):725-736. doi: 10.1016/j.iac.2024.08.004. Epub 2024 Sep 6.
7
Effectiveness of biologic switching in a real-life, Belgian severe asthma cohort.真实世界中比利时严重哮喘队列中的生物制剂转换的效果。
Immun Inflamm Dis. 2024 Oct;12(10):e70023. doi: 10.1002/iid3.70023.
8
Clinical and economic burden of severe asthma among US patients treated with biologic therapies.美国接受生物疗法治疗的重度哮喘患者的临床和经济负担。
Ann Allergy Asthma Immunol. 2021 Sep;127(3):318-325.e2. doi: 10.1016/j.anai.2021.03.015. Epub 2021 Mar 26.
9
Biologics in severe asthma: the overlap endotype - opportunities and challenges.严重哮喘中的生物制剂：重叠表型——机遇与挑战。
Expert Opin Biol Ther. 2020 Dec;20(12):1427-1434. doi: 10.1080/14712598.2020.1809651. Epub 2020 Aug 25.
10
Pediatric Severe Asthma in the Era of Biologic Treatments.生物治疗时代的儿童重症哮喘
Pediatr Allergy Immunol Pulmonol. 2020 Sep 1;33(3):118-120. doi: 10.1089/ped.2020.1249. Epub 2020 Sep 16.
引用本文的文献
1
Exploring the carbon footprint of severe asthma and change after biologic therapy initiation: an analysis of Northern Irish data.探索重度哮喘的碳足迹及生物制剂治疗开始后的变化：对北爱尔兰数据的分析。
ERJ Open Res. 2025 Jun 23;11(3). doi: 10.1183/23120541.01009-2024. eCollection 2025 May.
2
The role of mesenchymal stem cell‑derived exosomes in asthma (Review).间充质干细胞衍生外泌体在哮喘中的作用（综述）
Mol Med Rep. 2025 Jun;31(6). doi: 10.3892/mmr.2025.13531. Epub 2025 Apr 17.
本文引用的文献
1
Clinical remission with biologic therapies in severe asthma: a matter of definition.重度哮喘生物治疗的临床缓解：定义问题
Eur Respir J. 2023 Dec 14;62(6). doi: 10.1183/13993003.01844-2023. Print 2023 Dec.
2
Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.生物疗法治疗重症哮喘的临床缓解：来自英国重症哮喘注册研究的分析。
Eur Respir J. 2023 Dec 14;62(6). doi: 10.1183/13993003.00819-2023. Print 2023 Dec.
3
Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis.布地奈德福莫特罗治疗控制不佳哮喘患者的维持和缓解治疗的评价：系统评价和荟萃分析。
JAMA Netw Open. 2022 Mar 1;5(3):e220615. doi: 10.1001/jamanetworkopen.2022.0615.
4
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.每日一次单吸入器三联疗法（FF/UMEC/VI）与FF/VI治疗哮喘控制不佳患者的疗效和安全性（CAPTAIN）：一项双盲、随机、3A期试验
Lancet Respir Med. 2021 Jan;9(1):69-84. doi: 10.1016/S2213-2600(20)30389-1. Epub 2020 Sep 9.
5
SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis.轻至重度哮喘的SMART和按需治疗：一项网状Meta分析。
Eur Respir J. 2020 Sep 10;56(3). doi: 10.1183/13993003.00625-2020. Print 2020 Sep.
6
Budesonide/formoterol maintenance and reliever therapy in moderate-to-severe asthma: effects on eosinophilic airway inflammation.布地奈德/福莫特罗维持与缓解治疗中重度哮喘：对嗜酸性气道炎症的影响
Allergy Asthma Proc. 2014 Mar-Apr;35(2):141-7. doi: 10.2500/aap.2014.35.3729.
7
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.国际 ERS/ATS 指南：严重哮喘的定义、评估和治疗。
Eur Respir J. 2014 Feb;43(2):343-73. doi: 10.1183/09031936.00202013. Epub 2013 Dec 12.
8
Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial.有发生严重恶化风险的哮喘患者使用布地奈德/福莫特罗维持和缓解联用吸入器的疗效和安全性：一项随机对照试验。
Lancet Respir Med. 2013 Mar;1(1):32-42. doi: 10.1016/S2213-2600(13)70007-9. Epub 2013 Mar 4.
9
Budesonide/formoterol maintenance and reliever therapy via Turbuhaler versus fixed-dose budesonide/formoterol plus terbutaline in patients with asthma: phase III study results.布地奈德/福莫特罗维持和缓解治疗经都保与固定剂量布地奈德/福莫特罗加特布他林治疗哮喘患者的疗效比较：III 期研究结果。
Respirology. 2013 Feb;18(2):354-63. doi: 10.1111/resp.12009.
10
Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma.布地奈德/福莫特罗维持和缓解治疗在中国哮喘患者中的应用。
Chin Med J (Engl). 2012 Sep;125(17):2994-3001.
Zotero 插件